BIAF - bioaffinitytech.com Annual Revenue Growth (Last Twelve Months)

Brandmark of bioaffinitytech.com (BIAF)

The scalability of lung cancer diagnostics reduces costs through test standardization. The annual sales revenue trend over four quarters on the GURU.Markets chart demonstrates a trajectory where the -18.50 mark serves as a key metric. The success of bioAffinity Technologies (BIAF) is driven by cytometry experts who developed the high-precision non-invasive CyPath Lung sputum analysis for preventive oncology.

bioAffinity Technologies Inc. (BIAF) Sales Growth YoY (TTM): for the period 02/11/2024 - 11/16/2026

bioAffinity Technologies Inc. (BIAF) - metric breakdowns and financial figures

- stock price and consensus target price:
Summary company analytics:BIAF bioAffinity Technologies, Inc.
Finished products of bioAffinity Technologies, Inc.

For bioAffinity Technologies (BIAF), which integrates ESG standards into molecular diagnostics, this metric reflects the commercialization efficiency of eco-friendly digital solutions by calculating the rolling twelve-month revenue change. By analyzing the Last Twelve Months (LTM) trading revenue growth, an investor eliminates seasonality and assesses the actual scaling dynamics of the business, enabling the timely detection of stagnation and confirming the sustainability of the company's financial model.